INS and type 1 diabetes mellitus: found that Liraglutide 1.8 mg daily, compared to placebo, in add‐on to continuous subcutaneous insulin treatment for 26 weeks significantly reduced fat and lean mass by 4.6 and 2.5 kg, respectively, and the frequency of snack consumption and daily calorie resulting from simple carbohydrate intake by 27% in T1D patients with excess weight [40].